UNMIRI publishes quality framework for non-device clinical decision support

UNMIRI has released an ISO 9001-aligned framework for clinical decision support software that qualifies as non-device under federal law. The paper gives vendors a practical quality system for a fast-growing category of software that sits outside FDA device regulation but still affects clinical decisions.

Why it matters: - Non-device clinical decision support software has grown quickly, but vendors have had little guidance on how to run a clinical-grade quality system. - The framework gives developers a reference model for quality, risk management, and change control without requiring device status. - The approach matters for vendors trying to stay inside the FDA carve-out while still building software clinicians can trust.

What happened: - UNMIRI LLC published a quality-management framework for FDA Non-Device clinical decision support software. - The paper is available on SSRN: the full paper. - The paper is titled “An ISO 9001-Aligned Quality Management Framework for FDA Non-Device Clinical Decision Support Software Under the 21st Century Cures Act: A Reference Model with a Precision Oncology Worked Example.” - Co-authors are UNMIRI CEO Nida Uddin and CTO Umair Khan. - UNMIRI says the framework is voluntary and does not replace FDA jurisdiction if a product crosses into device territory.

The details: - The framework aligns with ISO 9001 and adapts it into a voluntary quality system for non-device decision support. - The paper includes a clause-by-clause cross-walk from ISO 9001 to non-device obligations. - It also includes a hazard taxonomy tied to the statutory criteria. - The paper adds a change-control procedure for clinically consequential knowledge updates. - A precision-oncology worked example shows how the framework applies in practice. - The 21st Century Cures Act created a carve-out under 21 U.S.C. 360j(o)(1)(E) that excludes qualifying clinical decision support from the FDA device definition. - FDA guidance revised in January 2026 draws the boundary of that carve-out. - Federal interoperability rules assign risk-management duties only to certified health-IT modules. - Standalone decision-support vendors therefore lack an established quality regime. - UNMIRI applies the model to its own platform, a set of cross-vendor precision-oncology APIs. - UNMIRI says the platform is designed to meet the Non-Device CDS criteria through structured inputs, options rather than directives, and a cited basis clinicians can review independently. - UNMIRI was founded in 2023 and is based in Langhorne, Pennsylvania.

Between the lines: - The paper is also a signal that the market may need a de facto standard before regulators set one. - By publishing a reference model, UNMIRI is positioning quality as an engineering discipline rather than a compliance afterthought. - The framework could help vendors defend their non-device status while also raising the bar for evidence, traceability, and change management.

What's next: - Vendors can adopt the framework, modify it, or use it as a benchmark for internal quality systems. - The model will likely get tested by developers building products near the FDA device boundary. - UNMIRI will continue using the framework on its own precision-oncology platform. - More information is available on UNMIRI’s website: the company’s site.

The bottom line: - UNMIRI is trying to fill a regulatory gray zone with a practical quality playbook for clinical decision support software that is not treated as a device.